NCT03249493 (MOVIDA-2) is a clinical trial of Blood sample on DBS in HIV/AIDS, sponsored by Institut Pasteur.

Who is sponsoring NCT03249493?

NCT03249493 is sponsored by Institut Pasteur.

What drugs are being tested in NCT03249493?

Interventions in NCT03249493: Blood sample on DBS.

What condition does NCT03249493 study?

NCT03249493 studies HIV/AIDS, Dried Blood Spot, Viral Load.

Is NCT03249493 still recruiting?

NCT03249493 is currently completed. Last updated 20 May 2022.

Last reviewed 2022-05-20 · How we verify

NCT03249493: MOVIDA-2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Monitoring Of Viral Load In Decentralised Area in Vietnam

Completed Last updated 20 May 2022

What this trial tests

trial testing Blood sample on DBS in HIV/AIDS in 584 participants. Completed in 1 September 2020.

Timeline

15 August 2017

Primary endpoint
1 August 2020

1 September 2020

Quick facts

Lead sponsor	Institut Pasteur
Status	Completed
Study type	OBSERVATIONAL
Enrollment	584
Start date	15 August 2017
Primary completion	1 August 2020
Estimated completion	1 September 2020
Sites	1 location across Vietnam

Drugs / interventions tested

Blood sample on DBS

Conditions studied

HIV/AIDS — all drugs for HIV/AIDS →
Dried Blood Spot — all drugs for Dried Blood Spot →
Viral Load — all drugs for Viral Load →

Sponsor

Institut Pasteur — full company profile →

Who can join

18 and older, any sex, with HIV/AIDS or Dried Blood Spot. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

As of today, HIV-infected patients followed in decentralized area have little or even no access to viral load monitoring because laboratories able to perform this biological measurement are only in large cities, and because plasma transfer to these laboratories is complex and very costly. Blood sampling using dried blood spots (DBS) could overcome these difficulties. The goal of this operational research is to document the feasibility of DBS use in decentralised area to monitor viral load, to evaluate the virological response on ART, and to compare the virological response between injecting drug users (IDU) and the other patients, as IDU represent a large proportion of HIV-infected patients who may have a lower access/adherence to care.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Feasibility of dried blood spots for HIV viral load monitoring in decentralized area in North Vietnam in a test-and-treat era, the MOVIDA project.
Nguyen TA, Tran TH, Nguyen BT, Pham TTP, et al · · 2020 · cited 6× · PMID 32271796 · DOI 10.1371/journal.pone.0230968
Assessment of HIV viral load monitoring in remote settings in Vietnam - comparing people who inject drugs to the other patients.
Lefrancois LH, Nguyen BT, Pham TTP, Le NTH, et al · · 2023 · cited 4× · PMID 36802388 · DOI 10.1371/journal.pone.0281857
Injecting drug use increases the risk of death in HIV patients on antiretroviral therapy in Vietnam.
Araujo Chaveron L, Pham TTP, Nguyen BT, Tran TH, et al · · 2024 · cited 2× · PMID 37339000 · DOI 10.1080/09540121.2023.2224549

Verify or expand the search:

Other recruiting trials for HIV/AIDS

Currently open trials in the same condition.

NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM · NA · recruiting
NCT07298785 — Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study · NA · recruiting
NCT07072481 — Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing · NA · recruiting
NCT07064785 — Video-Intervention to Inspire Treatment Adherence for Life for Adolescents · NA · recruiting
NCT07074899 — Evaluation of a Multi-Component Intervention to Support HIV Testing and Linkage to Services Among MSM in Peru · NA · active not recruiting

Other Institut Pasteur trials

Trials by the same sponsor.

NCT07205913 — Gut Microbiota, Diet-INDuced Obesity and Type 2 Diabetes in New Caledonia - MIND · not yet recruiting
NCT06945822 — Characterizing the Host Response to Leptospirosis for Better Diagnosis and Prognosis - NIHFI · NA · not yet recruiting
NCT05821478 — Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients · Phase 3 · recruiting
NCT06769815 — Host Immunity, Plasmodium and Pathogens Co-Infections · NA · not yet recruiting
NCT06718127 — Description of the Immune Response to Yellow Fever Vaccination · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03249493 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Pasteur
Last refreshed: 20 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03249493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing